99 results
P
patients with epilepsy
I/C
cannabidiol (CBD), control group
O
any grade AEs, severe grade AEs, serious AEs, AEs resulting in discontinuation, AEs resulting in dose reduction
P
ALK-TKIs
I/C
alectinib, criztotinib, brigatinib, ensartinib, ceritinib, lorlatinib, grade 3-4 AEs, fatal AEs, treatment discontinuation due to AEs
O
different toxicity spectra, safest ALK-TKI drug
P
patients with cancer
I/C
PD-1 and/or CTLA-4 immune checkpoint inhibitor treatments, different doses/exposures of ICI treatments
O
adverse events (AEs), treatment-related AE (trAE) and immune-mediated AE (imAE) rates
P
patients with advanced or metastatic urothelial carcinoma of the bladder (UCB)
I/C
chemotherapy regimens, different first-line chemotherapy regimens
O
mortality rates related to adverse events (AEs) and discontinuation of treatment due to toxicity as well as all AEs
P
adults with breast cancer
I/C
immune checkpoint inhibitors (ICIs), other conventional therapies
O
any-grade and grade 3-5 adverse events (AEs) and immune-related AEs (irAEs)
P
pancreatic insulinoma
I/C
endoscopic ultrasound (EUS)-guided ablation, minimally invasive surgery (MIS), adverse events (AEs), clinical and technical success rates, length of hospital stays, symptom recurrence rates
O
lower AE rate, shorter length of hospital stay, higher recurrence rate
P
advanced non-small cell lung cancer (NSCLC) patients
I/C
PD-1/PD-L1 inhibitors, traditional therapy
O
survival outcomes, adverse events (AEs), immune-related AEs (irAEs)
P
patients with type 2 diabetes mellitus (T2DM)
I/C
aquatic exercise (AE), land-based exercise (LE), non-intervention control (Ctrl)
O
6‑min walking distance (6MWD), maximal oxygen uptake (VO2max), resting heart rate (RHR), resting systolic (RSBP) and diastolic blood pressures (RDBP)
P
chloroquine or hydroxychloroquine users
I/C
use of chloroquine or hydroxychloroquine, controls
O
adverse events (AE)
P
critically ill patients
I/C
interhospital transport (IHT), conditions such as respiratory failure from coronavirus infection, stroke, and the need for extracorporeal membrane oxygenation
O
adverse events (AEs) during IHT